论文部分内容阅读
应用酶联免疫双抗夹心法对７８例胃癌患者血清可溶性白介素２－受体（ｓＩＬ－２Ｒ）和肿瘤坏死因子－α（ＴＮＦ－α）进行临床观察。结果发现：胃癌患者血清ｓＩＬ－２Ｒ和ＴＮＦ－α水平明显高于胃良性疾病和正常人（Ｐ＜０．０１）；Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期（Ｐ＜０．０１）；手术切除后（根治性或姑息性）ｓＩＬ－２Ｒ和ＴＮＦ－α显著下降（Ｐ＜０．０１）；手术后复发或转移患者血清中ｓＩＬ－２Ｒ和ＴＮＦ－α含量升高（Ｐ＜０．０１）；ｓＩＬ－２Ｒ和ＴＮＦ－α水平呈正相关（ｒ＝０．３３）；如果患者血清ｓＩＬ－２Ｒ含量高于１０００ｕ／Ｌ同时伴有ＴＮＦ－α持续高于１２０ｎｇ／ｍｌ，预兆生存期短。监测胃癌患者血清ｓＩＬ－２Ｒ和ＴＮＦ－α水平对临床诊断，病情估计和预后有重大意义。
The serum levels of soluble interleukin 2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in 78 patients with gastric cancer were observed by enzyme-linked immunosorbent assay (ELISA). The results showed that the serum levels of sIL-2R and TNF-α in gastric cancer patients were significantly higher than those in benign gastric diseases and normal controls (P<0.01). The levels of serum sIL-2R and TNF-α were higher in patients with stage III and IV than those in stage I and II (P<0.01). After excision (radical or palliative), sIL-2R and TNF-α were significantly decreased (P<0.01); serum sIL-2R and TNF-α levels were increased in patients with recurrence or metastasis after surgery (P<0.01). ); sIL-2R and TNF-α levels were positively correlated (r = 0.33); if the patient serum sIL-2R content is higher than 1000u/L while accompanied by TNF-α sustained higher than 120ng/ml, the omen survival time is short. Monitoring serum sIL-2R and TNF-α levels in gastric cancer patients is of great significance in clinical diagnosis, condition estimation and prognosis.